CLEO Diagnostics LtdASX: COV

Cleo Strengthens Cash Position with $1.7m R&D Tax Refund

· Issued by CLEO Diagnostics Ltd

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Following this refund, the company reports a strong cash balance, enabling it to pursue key milestones, including a pivotal clinical trial and FDA submission for its Pre-Surgical Ovarian Cancer Test. The CEO emphasized that this financial boost supports their critical phase of development and commercialization of technology aimed at transforming ovarian cancer detection.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

CLEO Diagnostics Ltd on 6ix

Earlier from CLEO Diagnostics

Later from CLEO Diagnostics

All CLEO Diagnostics news releases